XELOX for Metastatic Breast Cancer

A Phase II Trial of Capecitabine and Oxaliplatin in Metastatic Breast Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00204776

Enrollment

Registered

2005-09-20

Start date

2005-03-31

Completion date

2006-11-30

Last updated

2019-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Breast Cancer

Brief summary

Both capecitabine and oxaliplatin have single agent activity in breast cancer. The combination has improved activity in other solid tumors. This study seeks to assess the activity of the combination in breast cancer.

Interventions

DRUGCapecitabine and Oxaliplatin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* preserved organ function * good performance status * no more than one prior therapy * no active brain metastasis

Exclusion criteria

* No prior capecitabine or oxaliplatin * no con-current therapy

Design outcomes

Primary

Measure	Time frame
Overall response rate	—

Secondary

Measure	Time frame
Toxicity	—
Time to progression	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026